↓ Skip to main content

Oxycodone for pain in fibromyalgia in adults

Overview of attention for article published in Cochrane database of systematic reviews, September 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
13 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
54 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Oxycodone for pain in fibromyalgia in adults
Published in
Cochrane database of systematic reviews, September 2016
DOI 10.1002/14651858.cd012329
Pubmed ID
Authors

Helen Gaskell, R Andrew Moore, Sheena Derry, Cathy Stannard

Abstract

This review replaces part of an earlier review that evaluated oxycodone for both neuropathic pain and fibromyalgia, which has now been split into separate reviews for the two conditions. This review will consider pain in fibromyalgia only.Opioid drugs are commonly used to treat fibromyalgia, but they may not be beneficial for people with this condition. Most reviews have examined all opioids together. This review sought evidence specifically for oxycodone, at any dose, and by any route of administration. To assess the analgesic efficacy and adverse events of oxycodone for treating pain in fibromyalgia in adults. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE for randomised controlled trials from inception to 25 July 2016. We also searched the reference lists of retrieved studies and reviews, and searched online clinical trial registries. We planned to include randomised, double-blind trials of eight weeks' duration or longer, comparing oxycodone (alone or in fixed-dose combination with naloxone) with placebo or another active treatment. We did not include observational studies. The plan was for two independent review authors to extract data and assess trial quality and potential bias. Where pooled analysis was possible, we planned to use dichotomous data to calculate risk ratio and numbers needed to treat for one additional event, using standard methods. No study satisfied the inclusion criteria. Effects of interventions were not assessed as there were no included studies. We have only very low quality evidence and are very uncertain about estimates of benefit and harm. There is no randomised trial evidence to support or refute the suggestion that oxycodone, alone or in combination with naloxone, reduces pain in fibromyalgia.

Twitter Demographics

The data shown below were collected from the profiles of 13 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 54 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 13 24%
Student > Master 9 17%
Student > Bachelor 7 13%
Student > Doctoral Student 7 13%
Researcher 6 11%
Other 11 20%
Unknown 1 2%
Readers by discipline Count As %
Medicine and Dentistry 24 44%
Unspecified 14 26%
Psychology 6 11%
Nursing and Health Professions 5 9%
Mathematics 1 2%
Other 3 6%
Unknown 1 2%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 December 2018.
All research outputs
#1,739,456
of 12,600,310 outputs
Outputs from Cochrane database of systematic reviews
#4,425
of 10,376 outputs
Outputs of similar age
#49,025
of 260,782 outputs
Outputs of similar age from Cochrane database of systematic reviews
#88
of 177 outputs
Altmetric has tracked 12,600,310 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,376 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.2. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 260,782 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 177 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.